Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And this post is not an alert to $0.14plus to get out?
No need to 'chase' a stationary object regardless of whether it floats, rides on rails or has a greyhound badge.
WUHN Hijacked!
www.pumpsanddumps.com
We're expecting a huge bump in the share price of Wuhan General Group (WUHN) on Tuesday. HUGE! Like maybe as much as 2000%. And hardly anybody will make money. Mostly just the market makers and those who hijacked this symbol for their own greed. Why do we call them hijackers? Because the company has no idea this is coming and this is not being done by financiers or any other insiders. This Pump & Dump is being started on the street.
WUHN was formerly a NASDAQ traded company, but like many Chinese deals that don't have household names, a lack of interest in this one got it down listed to the OTC market. For all its compliance problems, the company's operation does seem to be on the up and up. In fact, we can't find a single suspicious event, although it does seem strange that the company filed its intent to conduct a one for 10 reverse split last June, but then never executed it. They probably figured that at best, all they would accomplish is a delay in the inevitable NASDAQ delisting.
Unlike most penny stock P & Ds, this one is a real company, actually conducting a real business. And yet, people will lose their asses on the stock.
What the hijackers have done, is found this company with great looking fundamentals, and a book value of $3.55 per share, trading under a nickel, making it an easy subject for a Pump & Dump. The company makes money hand over fist and in cash alone is worth about $1.24 per share. So why is it trading so low? Because rarely is an investor going to profit with this type of investment. As it is a Chinese company, the communist government has a stranglehold on the operations of the company. It will never be a takeover candidate. It is immune from its shareholders for any wrongdoing (who's going to sue it in China?). And dividends will not be paid. There is little if any upside to owning this type of company. The US stock markets are full of these kinds of profitable companies with anemic share prices.
So the hijackers come in and buy up some stock through the retail market from those that invested in it during its NASDAQ days. They paid pennies on the dollar. We figure that they've bought up a couple of hundred thousand shares over the last two weeks, at an expense of around 10 grand. Just look at the closing prices all the way back through December.
WUHN Closing Prices
Click to Enlarge
See how the stock suddenly found some interest over the last couple of weeks? That's called front loading. True, it's only a couple hundred thousand shares, but at a potential 1000% profit for the front loaders...well you get the idea. And now the trap is set.
So will you get stock for a nickel? A dime? Not a chance! We don't think retail buyers will get any at the open for as little as a quarter. You see, the Chinese own most of the stock and we promise you that they aren't selling for 10% of book value. So the result is that there is very little stock for sale. That isn't to say that their won't be any trades at a nickel dime or quarter on Tuesday morning. But we expect that those trades will be executed by the market makers who will be loading up before you and I can. We expect the stock to open at well over quarter and then for the same few hundred thousand shares to churn over. And over. And over. We wouldn't be surprised if the loose shares each traded 10 or 20 times on Tuesday, creating a false sense of volume. We also wouldn't be surprised if the stock trades up to or over a buck tomorrow. Demand will be that strong, thanks to the hype and the below book value state of the stock. The hijackers who front loaded will be cashing in a healthy profit. Their $10K investment could net them $100K - $200K. Not a bad day's scam.
The market makers will make even more if they short (as only they can) in the morning and then cover when shares come crashing down towards the close. And crash down they will. If not Tuesday night then Wednesday or Thursday. A lot of people are going to get suckered into this scheme.
Now if by chance the hijackers decide to keep this scheme going for a few days and bring in other stock pimps, the price may hold up for a couple of extra days. We don't think that will happen, but even then, nobody is going to see the kind of returns that the perpetrators of this hijacking will see. And the laws of gravity will inevitably apply to WUHN's share price. Gravity always applies.
Tuesday's action on WUHN will be the definition of a pyramid scheme.
LOAD UP THE BOAT BOYS AND GIRL WHILE THE PICKINGS ARE CHEAP
there's 1,000,000,000 shares authorized and expectations are that eventually they will all be issued, several times.
Three to four years is a reasonable time frame for things to start popping after a few rounds of dilutive financing in which the current shareholders get burnt badly.
could this be a 10 bagger soon?
this stuff appears fishy, are we getting some insiders information? where is the sec?
ALL I WANT IS TO SEE THIS MONSTER POP!!!!
Did you ever contact Gerald to ask how much Dr. Rubinfeld was compensated for his endorsement of the company's MANF technology?
It's my understanding that the good doctor received 1,000,000 shares of Reginicin stock for his endorsement of their product.
LOL No one is arguing but seems like you are bitter and need RE-ENTRY like you said earlier. I made a statement on what I believe can happen.
What IS predicatable is that there are very likely many rises and dips in AMBS pps ahead which render the 'get on this train' don't miss the bus' cliches meaningless. As stated, I AM doing what you suggest in your last sentence.
All I'm saying is you will wake up one day with buyout news or some real news that you won't be able to buy at these levels. Once again if you really believe in this company get the shares and trade all you want if you feel lucky.
If you had paid attention to my past posts, I'm here for the buyout, the big pharma offer, all or none. I have said this from day one. I don't flip, sell and buy back any stock I hold. I set a sell limit in my mind and I stick to that, and my sell point here with AMBS is a buyout, nothing less.
We have not seen "The big PR" yet.......
When NEWS hits, it will be to late.
Company officers have been known to purchase small amounts of stock to give the impression it is going up...so they can liquidate their shares @ a higher price. If they know it is going up they should put that news out for evryones knowledge.
Take some profits before they evaporate and look for a lower re-entry price.
The company is years away and millions of dollars in development costs from having any ability to potentially generate revenues. Purchasing an asset from a bankrupt company for $40,000 and trying to convince others that it's now worth millions of dollars is not easily accomplished.
The company has authorized 1,000,000,000 shares and I expect they will all eventually be issued. If they didn't anticipate the need for them then why authorize them?
MANF is a potential cure for Parkinsons disease
Current approved therapies treat only the symptoms of Parkinson’s disease. There is an urgent medical need for curative treatments for Parkinson’s disease that fills the fundamental gap in treatment: arresting disease progression. MANF, a neurotrophic factor indicated for the treatment of Parkinson’s disease, offers the promise of safely and effectively protecting dopamine producing neurons from death and rejuvenating dying cells to ultimately stop the progress of Parkinson’s disease and restore normal function to patients.
NEWS OUT..
http://www.otcmarkets.com/stock/AMBS/news
MANF has proven itself to be the superior drug for Parkinsons.
All of us who wrote to Gerald recieved very courteous and prompt replies.
if Michael says MANF or Amarantus tonight,
Gerald was making a presentation today, at 12 PM est....did he say something terribly bad?
i am thinking news om Thursday after the conferences
Interesting that the data that was expected in December was delayed almost three weeks.
Just saying.
Amarantus may or may not have the right treatment with their MANF,..
http://www.aimhighprofits.com/ambs-how-to-turn-500-into-20000-amarantus-bioscience-22543
Amarantus may or may not have the right treatment with their MANF, but by publicly discussing head injuries and their side effects, which include Parkinson’s disease, Alzheimer’s disease and other disorders in a symposium of their peers will be the make or break for new agreements or old share prices.
With how AMBS stock traded on Friday and the upcoming scheduled appearances for Amarantus BioScience, you would be equally foolish to not have it on your penny stocks to watch list for next week.
noticed a typo error in the calculation-Not a big deal-just an error-they are correcting.
Load the boat, don't miss the bus and above all else
don't let the UNGS train leave the station without you.
Good post, Banks.
Below is an important part of the addendum to the Seeking Alpha blog comments.
This is part III since it didn't all fit in the original.
There is also a strong belief among many traders and the company that illegal naked shorting is the primary difficulty faced by the company. You can see it in posts on chat boards and in company press releases. On November 26, 2012 the company issued a press release stating Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange. http://yhoo.it/X3qKwH
Then, even more interesting, the company actually changed it’s name by one letter in an effort to force a cover of naked shorts via the accounting of shares for the name change. On December 3, 2012 a press release came out stating Amarantus Completes Name Change and CUSIP Change. http://yhoo.it/131eZLF
They changed their name from Amarantus BioScienceS to Amarantus BioScience (no S at the end). This was quite the creative and inexpensive way to combat a naked short problem, if in fact, one existed. Could this be why the stock is up again now? Or, is it due to the stock promotion organizations, or the fundamentals?
The next key event that may cause the stock to run is the presentation of the Parkinson's neurorestoration animal data by CSO Dr. John Commissiong on January 8, 2013.
There will also be a concurrent scientific overview of the broader MANF opportunity by Dr. Joseph Rubinfeld, an Advisor to Amarantus. We may see .25 due to the hype leading up to this presentation. If the data doesn’t meet expectations, it may slide down again for the continuation of the roller coaster ride.
Not sure the presentations will change much as their effects has already taken place the past couple weeks thus explaining the upward mobility.
Can anyone predicting sell-offs of varying degrees, primarily because of locked up shares becoming available for sale, tell me how you've concluded, with amazing ceritiude in some cases, that all or most of the longs were excluded from that group, and how all or most of the traders are IN that group.
In effect you're asking us to believe, again, that the two groups are mutually exclusive and that most of the 'restriced' do not believe as the rest of us do in the short term potential pop from the conference, as well as the long term prospects for the company.
Are any of you 'unrestricted', who haven't sold during the recent run, saying that the 'restriced' are somehow 'needier or more finacially stressed than you?
I say that 'The Restricted'....sounds like a movie title.....are comprised of exactly the same mix of optimistic/pessimistic, confident/nervous, long term invsetors and short term traders as make up the rest of us. (I'm a 'non restricted' who has thus far not pulled the trigger on a sale. Not saying I won't, but if I sell it will be based on more than guess work about what others statistically no different in their makeup from me will do.)
House passes Senate Bill to avoid fiscal cliff. At least there won't likely be a broader market pull back to cloud investment decisions.
(IMPORTANT)The cause for the delay is the Company is conferring with leading academics and collaborators to confirm various aspects of the data results in order to ensure complete accuracy and transparency. The Company believes confirmation of the results with leaders in the field prior to release to the public is in the best interests of its shareholders.
confer with leading academics and collaborators to confirm various aspects of the data results in order to ensure complete accuracy and transparency
Again, they can only sell what they bought today. Can't sell old shares.
This....AMBS.... may seem pricey after playing around with this POS, but ADHC is too costly so far anyway, if you know what I mean. And I know that most of you do. Seriously, if you have ANY 'powder' left, you may be able to 'get well' quickly over here:
http://investorshub.advfn.com/Amarantus-BioSciences-Inc-AMBS-21711/
Time for a pullback? I keep thinking so, but so far it's defying gravity. Consider it a holiday gift from one still holding on to a lump of coal over here with the rest of you.
Now you should post the FDA orphan status guide so everyone can see how much easier it is.
Here is something to think about... You sure MANF is even classified as a drug.....
i am more interested in 2013 for possible fda approval on nuropro and lympro tests
FDA Approval Process
The FDA Drug and Biologic Approval Process: A hot topic
The high cost of prescription drugs is a hotly debated issue and poses a significant burden to individuals, families, and the federal government. Drug costs have led to Medicare Part D, a federally subsidized program meant to defray the costs of prescription drugs, particularly to the elderly. Though there are many contributing factors drug prices, their expense is due in part to the cost involved in completing the FDA approval process.
In order for pharmaceutical and biotech companies to market their drugs and biologics, companies must receive FDA approval, a rigorous, expensive, and time consuming process that can take over a decade to complete. Of 5000 compounds discovered in the pre-clinical stage, only about 5 will make it through the entire FDA approval process. Therefore, companies have to cover not only the cost of successful development of a single drug, but of many drugs that never make it to market.
The Phases in the FDA Approval Process
Pre-Clinical Phase
In the pre-clinical or drug discovery phase of the approval process, researchers look for potential new compounds to treat targeted diseases. Once a compound has been identified and refined to a formula that can be tolerated by humans, its toxicology is tested in animals and living tissue. The process takes roughly three and a half years. During this phase researchers look for:
•correct dosage level
•how frequently it should be administered
•the best delivery system (oral, topical, intravenous, etc.)
•short- and long-term survival of the animals
After pre-clinical testing is completed, the company then files an Investigational New Drug Application (IND) with the FDA. Fast Track Designation is an expedited review of a drug that is given to a company whose drug or biologic makes both a product and a marketing claim that addresses an unmet medical need. It can be granted at any point after the FDA approves an IND.
Phase I
If the FDA approves the IND, the experimental drug then moves into Phase I human testing. In this phase, the drug is tested in a small number (under 100) of healthy participants. Researchers look to see how well the drug is tolerated, how it is processed by the human body, and the correct dosing. This process takes a year.
Phase II
Once a compound is found to be well tolerated in healthy individuals, it is then tested for effectiveness for a targeted disease in a small number of patients. In this phase 100-300 people are administered the investigational drug to see if it actually works, and to determine its short-term effects. This process takes about two years.
Phase III
Phase III is a large-scale study of the effectiveness and side effects of the drug in a larger population, usually ranging from 1000-3000 patients. If the drug is submitted to the FDA for approval, the FDA will look at the Phase III data to determine if the drug is safe and effective. Aside from testing the drug’s viability, the company producing the drug also determines the logistics involved in creating a large supply of the treatment. Phase III of the FDA approval process takes about three years.
New Drug Application (NDA)/ Biologics License Application (BLA)
If the drug proves to be safe and effective, the company then files an NDA or BLA with the FDA. NDAs and BLAs are typically 100,000 pages long and include results of human and animal trials as well as information on how the drug is manufactured. It usually takes the FDA 1-2 years to complete the review process and approve a drug. However, there are cases when approval can be accelerated.
•At the time of application Priority Review can be granted to drugs that treat an unmet medical need.
•Orphan Drug Status is granted to drugs that treat rare diseases, or diseases that have no other available treatments.
Phase IV
Once a drug has received FDA approval it is then marketed to the general population. Short- and long-term side effects continue to be monitored and results are submitted to the FDA. Companies will also look for additional indication for the drug. In order for the drug to be approved for a new indication, it must receive approval from the FDA.
Read more: FDA Approval Process - FierceBiotech http://www.fiercebiotech.com/topics/fda_approval_process.asp#ixzz2G2WZ62ex
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech
I hope ambs not go in to spin on this data .
Awesome news.
I guess it will drop to 0.04 tomorrow,......